Gilead Sciences Ownership

GILD Stock  USD 65.42  0.15  0.23%   
Gilead Sciences secures a total of 1.25 Billion outstanding shares. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
 
Shares in Circulation  
First Issued
1990-06-30
Previous Quarter
1.3 B
Current Value
1.3 B
Avarage Shares Outstanding
1.3 B
Quarterly Volatility
460.5 M
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Gilead Sciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Gilead Sciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
The current year's Dividend Paid And Capex Coverage Ratio is expected to grow to 2.61, whereas Dividends Paid is forecasted to decline to about 3.4 B. The current year's Common Stock Shares Outstanding is expected to grow to about 1.5 B, whereas Net Income Applicable To Common Shares is forecasted to decline to about 4.9 B.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Gilead Stock Ownership Analysis

About 88.0% of the company shares are owned by institutional investors. The book value of Gilead Sciences was currently reported as 18.33. The company has Price/Earnings To Growth (PEG) ratio of 0.42. Gilead Sciences last dividend was issued on the 14th of March 2024. The entity had 2:1 split on the 28th of January 2013. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 14400 people. To learn more about Gilead Sciences call John Martin at 650 574 3000 or check out https://www.gilead.com.
Besides selling stocks to institutional investors, Gilead Sciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Gilead Sciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Gilead Sciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Gilead Sciences Quarterly Liabilities And Stockholders Equity

62.12 Billion

Gilead Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Gilead Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gilead Sciences backward and forwards among themselves. Gilead Sciences' institutional investor refers to the entity that pools money to purchase Gilead Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Norges Bank2023-12-31
16.1 M
Bank Of New York Mellon Corp2023-12-31
15.5 M
Northern Trust Corp2023-12-31
14 M
Legal & General Group Plc2023-12-31
12.5 M
Parnassus Investments Llc2023-12-31
12 M
Amvescap Plc.2023-12-31
11.6 M
Nuveen Asset Management, Llc2023-12-31
11.5 M
Royal Bank Of Canada2023-12-31
10.6 M
Amundi2023-12-31
10.5 M
Blackrock Inc2023-12-31
122.8 M
Vanguard Group Inc2023-12-31
111.8 M
Note, although Gilead Sciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Gilead Sciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gilead Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gilead Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gilead Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Gilead Sciences Outstanding Bonds

Gilead Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gilead Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gilead bonds can be classified according to their maturity, which is the date when Gilead Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Gilead Sciences Corporate Filings

F4
26th of April 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
25th of April 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F3
19th of April 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
13A
5th of April 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify

Gilead Sciences Investors Sentiment

The influence of Gilead Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Gilead. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Gilead Sciences.

Gilead Sciences Implied Volatility

    
  24.49  
Gilead Sciences' implied volatility exposes the market's sentiment of Gilead Sciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Gilead Sciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Gilead Sciences stock will not fluctuate a lot when Gilead Sciences' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gilead Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gilead Sciences' short interest history, or implied volatility extrapolated from Gilead Sciences options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.